Sam Chun Dang Pharm. Co., Ltd (000250.KQ)
KRW 142300.0
(1.14%)
KRW 142300.0
(1.14%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 192.66 Billion KRW | 8.65% |
| 2022 | 177.33 Billion KRW | 6.01% |
| 2021 | 167.27 Billion KRW | 0.25% |
| 2020 | 166.86 Billion KRW | -10.58% |
| 2019 | 186.6 Billion KRW | 16.66% |
| 2018 | 159.96 Billion KRW | -0.39% |
| 2017 | 160.58 Billion KRW | 8.97% |
| 2016 | 147.37 Billion KRW | 11.59% |
| 2015 | 132.06 Billion KRW | 11.05% |
| 2014 | 118.92 Billion KRW | 13.76% |
| 2013 | 104.54 Billion KRW | 36.39% |
| 2012 | 76.65 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 54.88 Billion KRW | 13.27% |
| 2024 Q1 | 48.45 Billion KRW | -7.69% |
| 2023 Q3 | 48.44 Billion KRW | 1.81% |
| 2023 Q4 | 52.49 Billion KRW | 8.36% |
| 2023 FY | 192.66 Billion KRW | 8.65% |
| 2023 Q1 | 44.15 Billion KRW | -0.78% |
| 2023 Q2 | 47.57 Billion KRW | 7.76% |
| 2022 FY | 177.33 Billion KRW | 6.01% |
| 2022 Q1 | 41.81 Billion KRW | -4.28% |
| 2022 Q2 | 47.18 Billion KRW | 12.83% |
| 2022 Q3 | 43.83 Billion KRW | -7.1% |
| 2022 Q4 | 44.5 Billion KRW | 1.54% |
| 2021 Q3 | 42.57 Billion KRW | 2.71% |
| 2021 Q1 | 39.56 Billion KRW | 0.31% |
| 2021 Q2 | 41.45 Billion KRW | 4.77% |
| 2021 Q4 | 43.68 Billion KRW | 2.62% |
| 2021 FY | 167.27 Billion KRW | 0.25% |
| 2020 Q2 | 44.32 Billion KRW | 6.68% |
| 2020 FY | 166.86 Billion KRW | -10.58% |
| 2020 Q4 | 39.43 Billion KRW | -5.07% |
| 2020 Q3 | 41.54 Billion KRW | -6.27% |
| 2020 Q1 | 41.55 Billion KRW | -6.77% |
| 2019 Q2 | 45.76 Billion KRW | 5.19% |
| 2019 Q1 | 43.5 Billion KRW | 13.6% |
| 2019 FY | 186.6 Billion KRW | 16.66% |
| 2019 Q4 | 44.56 Billion KRW | -15.54% |
| 2019 Q3 | 52.76 Billion KRW | 15.29% |
| 2018 Q2 | 41.4 Billion KRW | 3.67% |
| 2018 Q3 | 40.31 Billion KRW | -2.65% |
| 2018 Q4 | 38.29 Billion KRW | -5.0% |
| 2018 FY | 159.96 Billion KRW | -0.39% |
| 2018 Q1 | 39.94 Billion KRW | 4.61% |
| 2017 Q1 | 39.05 Billion KRW | -0.55% |
| 2017 FY | 160.58 Billion KRW | 8.97% |
| 2017 Q4 | 38.18 Billion KRW | -13.11% |
| 2017 Q2 | 39.39 Billion KRW | 0.87% |
| 2017 Q3 | 43.94 Billion KRW | 11.54% |
| 2016 FY | 147.37 Billion KRW | 11.59% |
| 2016 Q3 | 36.92 Billion KRW | 0.01% |
| 2016 Q4 | 39.27 Billion KRW | 6.35% |
| 2016 Q2 | 36.92 Billion KRW | 7.84% |
| 2016 Q1 | 34.24 Billion KRW | -2.6% |
| 2015 FY | 132.06 Billion KRW | 11.05% |
| 2015 Q3 | 34.27 Billion KRW | 6.46% |
| 2015 Q4 | 35.15 Billion KRW | 2.56% |
| 2015 Q2 | 32.19 Billion KRW | 5.79% |
| 2015 Q1 | 30.43 Billion KRW | -5.97% |
| 2014 Q2 | 29.13 Billion KRW | 4.8% |
| 2014 Q1 | 27.79 Billion KRW | 1.79% |
| 2014 FY | 118.92 Billion KRW | 13.76% |
| 2014 Q4 | 32.36 Billion KRW | 9.25% |
| 2014 Q3 | 29.62 Billion KRW | 1.69% |
| 2013 Q2 | 26.27 Billion KRW | 8.89% |
| 2013 Q3 | 26.82 Billion KRW | 2.11% |
| 2013 Q1 | 24.13 Billion KRW | 0.0% |
| 2013 Q4 | 27.3 Billion KRW | 1.79% |
| 2013 FY | 104.54 Billion KRW | 36.39% |
| 2012 FY | 76.65 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Hyundai Bioscience Co., Ltd. | 9.48 Billion KRW | -1932.072% |
| ST Pharm Co.,Ltd. | 284.99 Billion KRW | 32.395% |
| ABL Bio Inc. | 65.54 Billion KRW | -193.939% |
| Cellid, Co., Ltd. | - KRW | -Infinity% |